← All trials
NCT02878265
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2011
- Primary completion
- May 1, 2012
- Completion date
- Dec 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 547
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- University of GhanaLead sponsor
- University of GhanaOverall official - principal investigator
- University of GhanaReponsible party - principal investigator
- Kwame Nkrumah University of Science and TechnologyStudy chair
- Kwame Nkrumah University of Science and TechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.